These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

825 related articles for article (PubMed ID: 19890126)

  • 1. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.
    Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Essahsah F; Fathers LM; Offringa R; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; van der Burg SH; Melief CJ
    N Engl J Med; 2009 Nov; 361(19):1838-47. PubMed ID: 19890126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia.
    Baldwin PJ; van der Burg SH; Boswell CM; Offringa R; Hickling JK; Dobson J; Roberts JS; Latimer JA; Moseley RP; Coleman N; Stanley MA; Sterling JC
    Clin Cancer Res; 2003 Nov; 9(14):5205-13. PubMed ID: 14614000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins.
    Davidson EJ; Boswell CM; Sehr P; Pawlita M; Tomlinson AE; McVey RJ; Dobson J; Roberts JS; Hickling J; Kitchener HC; Stern PL
    Cancer Res; 2003 Sep; 63(18):6032-41. PubMed ID: 14522932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spontaneous regression of grade 3 vulvar intraepithelial neoplasia associated with human papillomavirus-16-specific CD4(+) and CD8(+) T-cell responses.
    Bourgault Villada I; Moyal Barracco M; Ziol M; Chaboissier A; Barget N; Berville S; Paniel B; Jullian E; Clerici T; Maillère B; Guillet JG
    Cancer Res; 2004 Dec; 64(23):8761-6. PubMed ID: 15574788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
    Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
    Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; van der Burg SH; Melief CJ
    Clin Cancer Res; 2008 Jan; 14(1):169-77. PubMed ID: 18172268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
    Seo SH; Jin HT; Park SH; Youn JI; Sung YC
    Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response.
    van Poelgeest MI; Welters MJ; Vermeij R; Stynenbosch LF; Loof NM; Berends-van der Meer DM; Löwik MJ; Hamming IL; van Esch EM; Hellebrekers BW; van Beurden M; Schreuder HW; Kagie MJ; Trimbos JB; Fathers LM; Daemen T; Hollema H; Valentijn AR; Oostendorp J; Oude Elberink JH; Fleuren GJ; Bosse T; Kenter GG; Stijnen T; Nijman HW; Melief CJ; van der Burg SH
    Clin Cancer Res; 2016 May; 22(10):2342-50. PubMed ID: 26813357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human papillomavirus infections and vulvar disease development.
    Garland SM; Insinga RP; Sings HL; Haupt RM; Joura EA
    Cancer Epidemiol Biomarkers Prev; 2009 Jun; 18(6):1777-84. PubMed ID: 19505910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals.
    Palefsky JM; Berry JM; Jay N; Krogstad M; Da Costa M; Darragh TM; Lee JY
    AIDS; 2006 May; 20(8):1151-5. PubMed ID: 16691066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination against HPV-16 for vulvar intraepithelial neoplasia.
    Bourgault Villada I
    N Engl J Med; 2010 Feb; 362(7):655-6; author reply 656. PubMed ID: 20164490
    [No Abstract]   [Full Text] [Related]  

  • 12. Human papillomavirus vaccine for cancer prevention.
    Finn OJ; Edwards RP
    N Engl J Med; 2009 Nov; 361(19):1899-901. PubMed ID: 19890134
    [No Abstract]   [Full Text] [Related]  

  • 13. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species.
    Gambhira R; Gravitt PE; Bossis I; Stern PL; Viscidi RP; Roden RB
    Cancer Res; 2006 Dec; 66(23):11120-4. PubMed ID: 17145854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses.
    Welters MJ; Kenter GG; de Vos van Steenwijk PJ; Löwik MJ; Berends-van der Meer DM; Essahsah F; Stynenbosch LF; Vloon AP; Ramwadhdoebe TH; Piersma SJ; van der Hulst JM; Valentijn AR; Fathers LM; Drijfhout JW; Franken KL; Oostendorp J; Fleuren GJ; Melief CJ; van der Burg SH
    Proc Natl Acad Sci U S A; 2010 Jun; 107(26):11895-9. PubMed ID: 20547850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
    Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ
    Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of an adenoviral vaccine against E6 and E7 oncoproteins to prevent growth of human papillomavirus-positive cancer.
    Lee DW; Anderson ME; Wu S; Lee JH
    Arch Otolaryngol Head Neck Surg; 2008 Dec; 134(12):1316-23. PubMed ID: 19075129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive.
    Muderspach L; Wilczynski S; Roman L; Bade L; Felix J; Small LA; Kast WM; Fascio G; Marty V; Weber J
    Clin Cancer Res; 2000 Sep; 6(9):3406-16. PubMed ID: 10999722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human papillomavirus type 16 and risk of preinvasive and invasive vulvar cancer: results from a seroepidemiological case-control study.
    Hildesheim A; Han CL; Brinton LA; Kurman RJ; Schiller JT
    Obstet Gynecol; 1997 Nov; 90(5):748-54. PubMed ID: 9351758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integration of HPV-16 and HPV-18 DNA in vulvar intraepithelial neoplasia.
    Hillemanns P; Wang X
    Gynecol Oncol; 2006 Feb; 100(2):276-82. PubMed ID: 16300821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The etiologic role of HPV in vulvar squamous cell carcinoma fine tuned.
    van de Nieuwenhof HP; van Kempen LC; de Hullu JA; Bekkers RL; Bulten J; Melchers WJ; Massuger LF
    Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2061-7. PubMed ID: 19567503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.